Joint Research on AI Drug Discovery Featured at the 46th Annual Meeting of the Molecular Biology Society of Japan

Joint Research On AI Drug Discovery Featured At The 46th Annual Meeting Of The Molecular Biology Society Of Japan

From December 6th to 8th, at the “46th Annual Meeting of the Molecular Biology Society of Japan” held in Kobe, the results of collaborative research conducted by the University of Tokyo and HACARUS will be presented. The collaborative research focuses on AI drug discovery aimed at developing treatments for Alzheimer’s and Parkinson’s diseases.

Presentation Schedule:

December 8th (Friday) 9:30-11:45

Session 3AS-17: Bridging the Gap between Basic and Clinical Research in Neurodegenerative Disease

Toward translational research of neurodegenerative disease

Organizers (Titles omitted)

Yuzuru Imai (Juntendo University), Genta Ito (Teikyo University)

Details

The prevalence of elderly neurodegenerative diseases, represented by Alzheimer’s and Parkinson’s diseases, is expected to continue to increase. Overcoming these conditions remains a significant challenge. Regarding Alzheimer’s disease, an anti-amyloid β antibody has been approved as a disease-modifying drug. In Parkinson’s disease, a third-phase trial is underway for an LRRK2 kinase inhibitor. The development of these therapeutic agents is the result of bridging basic and clinical research. However, in Japan, there are limited opportunities for collaboration between basic and clinical researchers, posing a barrier to bridging the gap in achievements. This symposium aims to bring together leading researchers in both fields, providing an opportunity to establish a research network.

Abstract

Elucidation of the lysosomal positioning mechanism by the Parkinson’s disease-causing kinase LRRK2

Presenters from HACARUS

Yuta Katai, Yuki Nishimura, Sota Imotani, Haruki Inoue

About HACARUS

HACARUS INC, on a mission to bring the next generation of instruments to every industry, has since its founding in 2014, supplied AI solutions across the medical, manufacturing and construction fields in Japan – and beyond. Headquartered in Kyoto, Japan, and backed by Daikin, Osaka Gas and Miyako Capital (Kyoto University), among others, its technology enables humans to make better, faster, and more reliable decisions based on data-driven insights. HACARUS’ proprietary AI engine is built using Sparse Modeling, a method that understands data like a human would – by its unique key features and is far more resource, time, and energy-efficient when compared to Deep Learning. To learn more, visit https://hacarus.com

Subscribe to our newsletter

Click here to sign up